Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trialPerry B. Shieh, Salvador Rico, A. Seferian et al.|The Lancet Neurology|2023Cited by 120
Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysisRobert J. Graham, Alan H. Beggs, Francesco Muntoni et al.|Archives of Disease in Childhood|2019Cited by 43